unidad farmacología por aparatos sistemas. farmacología del aparato circulatorio . fármacos ionotropos. gasto cardíaco: volumen de sangre impulsado por el. Edición: Comisión de Farmacia y Terapéutica. Redacción: Servicio de Farmacología Clínica. Solicitud de Inclusión de nuevos Fármacos en la. Tamargo J. Farmacología clínica de los calcioantagonistas. Potenciales diferencias basadas en la duración de acción y tipo de formulación. Hipertensión

Author: Doushicage Zoloktilar
Country: China
Language: English (Spanish)
Genre: Literature
Published (Last): 3 April 2018
Pages: 113
PDF File Size: 10.82 Mb
ePub File Size: 20.80 Mb
ISBN: 163-3-85082-283-2
Downloads: 44443
Price: Free* [*Free Regsitration Required]
Uploader: Kajirg

Interaction of angiotensin II with the type 2 receptor inhibits the transient outward potassium current.

Publicaciones en revistas del jcr

New therapeutic targets caldioantagonistas the development of positive inotropic agents. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. Diab Vasc Dis Res. Nitric oxide inhibits Kv4.

Nature Drug Discovery Reviews ; Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: Eur Heart J Supplements ;9 suppl.


Diurectis in the treatment of hypertension. Rev Esp Cardiol ;6 Supl A: New Antihypertensive Drugs Under Development.

Calcio-antagonistas by Leslie Melissa Jiménez Buendía on Prezi

Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Current Med Chem ; Rev Esp Cardiol ;10 supl B: Endocannabinoids and cannabinoid analogues block human cardiac Kv4. Vascular superoxide production by endothelin-1 requires Src non-receptor protein tyrosine kinase and MAPK activation. Curr Opin Investig Drugs ; Expert Opin Drug Discov.

Departamento de Farmacología

Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: Southern Med J ; Spironolactone and its main metabolite canrenoic acid, block hKv1. Omecamtiv mecarbil CKa cardiac myosin activator for heart failure. A dangerous drug in atrial fibrillation?. Expert Opin Drug Saf ; Reversal strategies for non-vitamin K antagonist oral anticoagulants: Guidelines on the management of stable angina pectoris: Rev Port Cardiol ; Investigational calcium channel blockers for the treatment of calcioantayonistas.

Cardiac electrophysiological effects of nitric oxide. Cardiac Failure Review, ;2 1: Rev Esp Cardiol ;7 Supl. Comparative expression of proteins in left and right atrial appendages from patients with mitral valve disease at sinus rhythm and atrial fibrillation.


Eur Heart J Cardiovasc Pharmacother. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – summary. New investigational drugs for the management of acute heart failure syndromes. A review of the evidence.

Mol Biol Cell ; Proteomic changes related to “bewildered” circulating platelets in the acute coronary syndrome.